Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study

S. A. Peeters, L. Engelen, J. Buijs, A. Jorsal, H. -H. Parving, L. Tarnow, P. Rossing, C. G. Schalkwijk, C. D. A. Stehouwer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number55
Number of pages12
JournalCardiovascular Diabetology
Volume16
DOIs
Publication statusPublished - 26 Apr 2017

Keywords

  • Type 1 diabetes
  • Cardiovascular disease
  • All-cause mortality
  • Matrix metalloproteinase
  • Tissue inhibitor of metalloproteinase
  • Estimated glomerular filtration rate
  • EURODIAB PROSPECTIVE COMPLICATIONS
  • TISSUE INHIBITOR
  • MYOCARDIAL-INFARCTION
  • HEART-FAILURE
  • MICROVASCULAR COMPLICATIONS
  • MATRIX-METALLOPROTEINASE-9
  • DYSFUNCTION
  • RETINOPATHY
  • MELLITUS
  • EVENTS

Cite this